The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
FDA grants Idhifa® (enasidenib) approval for the treatment of R/R AML patients with IDH2 mutation
On 1st August 2017, the U.S. Food and Drug Administration (FDA) granted approval to Idhifa® (enasidenib) for the treatment of adult patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) with an Isocitrate Dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.1 The approval comes after the priority review designation granted to enasidenib in March 2017, which was reported here.
This approval for enasidenib, a first in class, oral, selective inhibitor of mutations in IDH2, was based on results from the phase I/II AG-221 AML-001 study (NCT01915498). In this study, the efficacy of enasidenib, was assessed in R/R AML patients (median age = 68 years) with mutant IDH2. Patients were orally administered enasidenib at a starting dose of 100 mg daily until disease progression or unacceptable toxicity. The key results were:
- Complete Response/ Complete Response with Partial Hematologic Improvement (CR/CRh); 23%
The safety of enasidenib was also assessed in 214 R/R IDH2 mutated AML patients in this study. The key results were:
- 30-day and 60-day mortality rates were 4.2% (9/214) and 11.7% (25/214) respectively
- Adverse Events (AEs) included indirect hyperbilirubinemia and IDH-inhibitor-associated differentiation syndrome (14%)
In summary, enasidenib was well-tolerated and induced hematologic responses in mutant IDH2 R/R AML patients.2 More results from this phase I/II AG-221 AML-001 study are reported here.
Idhifa® was approved alongside the Abbott RealTime™ IDH2 companion diagnostic test, which is FDA-approved as an aid in identifying IDH2 mutated AML patients for treatment with Idhifa®.
References